TY - JOUR
T1 - Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design
T2 - Rationale and design
AU - de Wilde, Arno
AU - van Maurik, Ingrid S.
AU - Kunneman, Marleen
AU - Bouwman, Femke
AU - Zwan, Marissa
AU - Willemse, Eline A. J.
AU - Biessels, Geert Jan
AU - Minkman, Mirella
AU - Pel, Ruth
AU - Schoonenboom, Niki S. M.
AU - Smets, Ellen M. A.
AU - Wattjes, Mike P.
AU - Barkhof, Frederik
AU - Stephens, Andrew
AU - van Lier, Erik J.
AU - Batrla-Utermann, Richard
AU - Scheltens, Philip
AU - Teunissen, Charlotte E.
AU - van Berckel, Bart N. M.
AU - van der Flier, Wiesje M.
PY - 2017
Y1 - 2017
N2 - The Alzheimer's biomarkers in daily practice (ABIDE) project is designed to translate knowledge on diagnostic tests (magnetic resonance imaging [MRI], cerebrospinal fluid [CSF], and amyloid positron emission tomography [PET]) to daily clinical practice with a focus on mild cognitive impairment (MCI). ABIDE is a 3-year project with a multifaceted design and is structured into interconnected substudies using both quantitative and qualitative research methods. Based on retrospective data, we develop personalized risk estimates for MCI patients. Prospectively, we collect MRI and CSF data from 200 patients from local memory clinics and amyloid PET from 500 patients in a tertiary setting, to optimize application of these tests in daily practice. Furthermore, ABIDE will develop strategies for optimal patient-clinician conversations. Ultimately, this will result in a set of practical tools for clinicians to support the choice of diagnostic tests and facilitate the interpretation and communication of their results
AB - The Alzheimer's biomarkers in daily practice (ABIDE) project is designed to translate knowledge on diagnostic tests (magnetic resonance imaging [MRI], cerebrospinal fluid [CSF], and amyloid positron emission tomography [PET]) to daily clinical practice with a focus on mild cognitive impairment (MCI). ABIDE is a 3-year project with a multifaceted design and is structured into interconnected substudies using both quantitative and qualitative research methods. Based on retrospective data, we develop personalized risk estimates for MCI patients. Prospectively, we collect MRI and CSF data from 200 patients from local memory clinics and amyloid PET from 500 patients in a tertiary setting, to optimize application of these tests in daily practice. Furthermore, ABIDE will develop strategies for optimal patient-clinician conversations. Ultimately, this will result in a set of practical tools for clinicians to support the choice of diagnostic tests and facilitate the interpretation and communication of their results
KW - Alzheimer's disease
KW - Biomarkers
KW - Clinical practice
KW - Dementia
KW - Mild cognitive impairment
UR - http://www.scopus.com/inward/record.url?scp=85013119832&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.dadm.2017.01.003
DO - https://doi.org/10.1016/j.dadm.2017.01.003
M3 - Article
C2 - 28239639
SN - 2352-8729
VL - 6
SP - 143
EP - 151
JO - Alzheimer's & dementia : diagnosis, assessment & disease monitoring
JF - Alzheimer's & dementia : diagnosis, assessment & disease monitoring
ER -